Twist Bioscience Stock Offered in IPO

October 4. 2018. 5 mins read

Just a few weeks ago, we published a piece on 9 DNA Data Storage Companies to Watch, one of which was a startup called Twist Bioscience. After taking in just over $253 million from 24 different investors including Illumina (third largest shareholder with 7.7%) and asset manager Fidelity, Twist Bioscience has filed for an Initial Public Offering (IPO) which one might argue is the most exciting synthetic biology IPO we’ve seen to date. Let’s dig into the IPO filing and see what retail investors will be getting themselves into if they decide to purchase Twist Bioscience stock.

Twist Bioscience – Synthetic DNA at Scale

Click for company websiteSimply put, Twist Bioscience leverages technology found in the semiconductor industry to create synthetic DNA at a much cheaper cost than anyone else at scale. Here’s an excerpt from the filing which describes just how much better their methods are (our emphasis in bold).

Our silicon-based chip technology is able to increase DNA production by a factor of 9,600 on a footprint similar to that of traditional DNA synthesis methods. Also, it significantly lowers the volume of required reagents, specifically the most expensive reagent

Become a premium member and get access to hundreds of premium articles, reports and additional content.

Nanalyze Premium is your comprehensive guide to investing in disruptive technologies. Read by the top investment banks, management consultancies, VCs, and research houses. Trusted by over 100,000 institutional and retail investors. Covering disruptive technologies for over 18 years.